Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author.

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.

IBS has classically been regarded as a “diagnosis of exclusion,” but new research suggested that might be changing with better diagnostic and treatment approaches.

To sign up for Becker's GI & Endoscopy E-Newsletter or any of our other E-Newsletters, click here. If you are experiencing difficulty receiving our newsletters, you ...